Table 1 Baseline characteristics of the included patients
Characteristic | Phase Ia | Phase Ib | Total |
|---|---|---|---|
(n = 99) | (n = 419) | (n = 518) | |
Age, median (years) | 50 | 55 | 53 |
 Range (years) | 24–81 | 20–80 | 20–81 |
Sex, n (%) | |||
 Male | 74 (74.7) | 244 (58.2) | 318 (61.4) |
 Female | 25 (25.3) | 175 (41.8) | 200 (38.6) |
ECOG performance status, n (%) | |||
 0 | 33 (33.3) | 69 (16.5) | 102 (19.7) |
 1 | 66 (66.7) | 350 (83.5) | 416 (80.3) |
Tumor type, n (%) | |||
 NSCLC | 38 (38.4) | 108 (25.8) | 146 (28.2) |
 NPC | 55 (55.6) | 79 (18.9) | 134 (25.9) |
 CC | 0 | 55 (13.1) | 55 (10.6) |
 CRC | 0 | 27 (6.4) | 27 (5.2) |
 SCLC | 1 (1.0) | 25 (6.0) | 26 (5.0) |
 HCC | 0 | 25 (6.0) | 25 (4.8) |
 Biliary tract carcinoma | 0 | 21 (5.0) | 21 (4.1) |
 Breast cancer | 0 | 19 (4.5) | 19 (3.7) |
 Kidney cancer | 0 | 18 (4.3) | 18 (3.5) |
 Ovarian cancer | 0 | 8 (2.0) | 8 (1.5) |
 Other | 5 (5.1) | 34 (8.1) | 39 (7.5) |
Metastasis, n (%) | |||
 No | 0 | 8 (2.0) | 8 (1.5) |
 Yes | 99 (100.0) | 411 (98.1) | 510 (98.5) |
History of immunotherapy, n (%) | 46 (46.5) | 134 (32.0) | 180 (34.7) |
Prior lines of therapy, n (%) | |||
 0 | 2 (2.0) | 22 (5.3) | 24 (4.6) |
 1–2 | 59 (59.6) | 261 (62.3) | 320 (61.8) |
 3–4 | 30 (30.3) | 93 (22.2) | 123 (23.7) |
 ≥ 5 | 8 (8.1) | 40 (9.5) | 48 (9.3) |
 Unknown | 0 | 3 (0.7) | 3 (0.6) |